Incyte has broken off its immuno-oncology deal with Agenus. The step, which follows a series of program terminations, will give Agenus full control of assets that it will consider advancing internally ...
The biotech sector has been in focus in the past week with key pipeline and regulatory updates. Among these, Biogen reports first-quarter results while Incyte gets FDA approval for novel cream ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Incyte (INCY – Research Report) and BioMarin Pharmaceutical (BMRN – Research Report). Incyte (INCY) Mizuho Securities ...
Incyte is sticking to its strategy this year of finding “early-stage, exotic stuff”—paying Genesis Therapeutics $30 million upfront to use the biotech’s artificial intelligence platform to develop ...
Microcarrier-based platforms have transformed scalable cell culture for a wide range of applications, from cell therapy and vaccine production to cultured meat. Viable cell density (VCD) monitoring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results